Meet Juandré Klopper, the man giving public healthcare a lifeline
Many see the sector's issues as unsolvable, but Juandré Kopper has a different perspective.
'To work on a broken health system, some might say it's futile. It always seems impossible, until it is done,' Klopper told News24.
He is the founder of Sponsor Medic, a non-profit organisation that aims to support the health system by raising donations and paying doctors to work in hospitals and clinics where the need is the greatest.
Klopper grew up watching his grandfather serve Durban's poorest patients. Helping those who needed it most has become deeply tied to his purpose.
'I remember the story my father and my grandmother told me after his passing. One of his patients had a son who was doing very well in school, and my grandfather actually paid for him to go to university, study medicine and become a doctor himself.'
In January 2024, South African healthcare facilities saw deep budget cuts in an attempt to sustain fiscal balance on a national scale.
'I printed my printer dry twice, sending out CVs.'
This bittersweet, almost divine intervention allowed Klopper to lean into his side projects.
'Something that comes your way that looks like bad luck is actually a good thing sometimes.'
Klopper started raising corporate and non-profit organisations' funds to allocate health workers to medical rooms under severe pressure, elevating emergency rooms and decreasing patient waiting times.
So, Sponsor Medic was born for the sole purpose of public health facilities.
In the short time Sponsor Medic has been in operation, it has helped more than 1 600 patients.
'I think the beautiful part of our work is that we don't necessarily see the impact we make because we prevent chaos. If we do our work correctly, things should just be going on as normal.'
Inspired by Nelson Mandela's courage in the fight against apartheid, Klopper compared the late president to David in a David and Goliath fight.
'He took on a massive challenge, he took it on with a lot of courage, and a lot of humility, and that for me is inspiring, and it's worth remembering that what he did, he did for others, and he gave a lot of himself, so that other may live a better life, I think that is truly inspiring.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
30 minutes ago
- Forbes
Rethinking Work With AI: What Stanford's Groundbreaking Workforce Study Means For Healthcare's Future
AI systems should reduce cognitive load, clarify ambiguity, and work alongside teams as intelligent collaborators, not as black-box disruptors. What if the AI systems you're building solve the wrong problems and alienate the workforce you're trying to support? That's the uncomfortable reality laid bare by a new research study from Stanford University. While AI pilots race ahead across administrative and clinical functions, most are still built on a flawed assumption: that automating tasks equals progress. But for the people doing the work—clinicians, care coordinators, billing specialists—that's not what they asked for. The report, Future of Work with AI Agents, offers the most granular audit yet of how worker sentiment, task complexity, and technical feasibility collide in the age of artificial intelligence. Over 1,500 U.S. workers were surveyed across 104 occupations, producing the most detailed dataset yet on where AI could, and should, fit. Their preferences were paired with ratings from 52 AI experts to create a map of the true automation and augmentation landscape. For healthcare, the findings could not come at a more urgent moment. The healthcare sector faces a burned-out workforce, escalating administrative waste, and widespread dissatisfaction with digital tools that were meant to help. A majority of physicians report that documentation burden is a leading cause of burnout, with recent studies showing U.S. physicians spend excessive time on documentation tasks. Nurse attrition has also remained a concern since the pandemic. Meanwhile, AI adoption is surging, with the vast majority of health systems piloting or planning AI integration. However, there remains a lack of consistent frameworks to align these technologies with real-world clinical and operational dynamics. The result? Misplaced investment, fractured trust, and resistance from the very people AI is meant to assist. The Stanford study confirms it: the majority of tasks that healthcare workers want automated—like documentation, claims rework, or prior auth form generation—are not where AI tools are being focused. In fact, less than 2% of those high-desire tasks are showing up in actual LLM usage today. Instead, attention and venture funding are often diverted toward automating interpersonal communication, appeals, or triage. These are areas where trust, nuance, and empathy matter most. This is more than a technical oversight. It's a strategic miscalculation. This study clarifies that the future of AI in healthcare isn't about replacing human judgment—it's about protecting it. Leaders must pivot from automation-at-any-cost to augmentation-by-design. That means building AI systems that reduce cognitive load, clarify ambiguity, and work alongside teams as intelligent collaborators, not as black-box disruptors. And, most critically, it means listening to the workforce before you deploy. A New Lens on Work: Automation Desire vs. Technical Feasibility Stanford's framework introduces two powerful filters for every task: what workers want automated and what AI can do. This produces a four-quadrant map: This approach is especially revealing in healthcare, where: Critically, 69% of workers said their top reason for wanting AI was to free up time for higher-value work. Only 12% wanted AI to fully take over a task. The takeaway? Augmentation, not replacement. Green Light (Automate Now): R&D Opportunity (Invest in Next-Gen AI): Red Light (Approach with Caution): Y Combinator is one of the world's most influential startup accelerators, known for launching and funding early-stage technology companies, including many that shape the future of artificial intelligence. Its relevance in this context comes from its outsized role in setting trends and priorities for the tech industry: the types of problems YC-backed startups pursue often signal where talent, investment, and innovation are headed. The Stanford study highlights a striking disconnect between these startup priorities and actual workforce needs. Specifically, it found that 41% of Y Combinator-backed AI startups are developing solutions for tasks that workers have little interest in automating—referred to as 'Red Light Zones' or low-priority areas. This reveals a substantial missed opportunity: if leading accelerators like Y Combinator better aligned their focus with the real needs and preferences of the workforce, AI innovation could deliver far greater value and acceptance in the workplace. The Human Agency Scale: AI as a Teammate To move beyond binary thinking (automate vs. don't), the Stanford research team introduces a more nuanced framework: the Human Agency Scale (HAS). This five-tier model offers a conceptual scaffold for evaluating how AI agents should integrate into human workflows. Rather than asking whether a task should be automated, the HAS asks to what extent the human remains in control, how decision-making is shared, and what level of oversight is required. The scale ranges from H1 to H5, as follows: The Stanford study reveals a clear pattern across occupations: the majority of workers—particularly in healthcare—prefer H2 or H3. Specifically, 45.2% of tasks analyzed across all industries favor an H3 arrangement, in which AI acts as a collaborative peer. In healthcare contexts—where judgment, empathy, and contextual nuance are foundational—H3 is even more critical. In roles such as care coordination, utilization review, and social work, tasks often require a mix of real-time decision-making, human empathy, and risk stratification. A system built for full automation (H5) in these contexts would not only be resisted—it would likely produce unsafe or ethically problematic outcomes. Instead, what's required are AI agents that can surface relevant information, adapt to the evolving contours of a task, and remain responsive to human steering. John Halamka, President of Mayo Clinic Platform, reinforced this collaborative mindset in February 2025: 'We have to use AI,' he said, noting that ambient listening tools represent 'the thing that will solve many business problems' with relatively low risk. He cited Mayo's inpatient ambient nursing solutions, which handle '100% of the nursing charting without the nurse having to touch a keyboard,' but was clear that these tools are 'all augmenting human behavior and not replacing the human.' These insights echo a broader workforce trend: automation without agency is unlikely to succeed. Clinical leaders don't want AI to dictate care pathways or handle nuanced appeals independently. They want AI that reduces friction, illuminates blind spots, and extends their cognitive reach, without erasing professional identity or judgment. As such, designing for HAS Level 3 (equal partnership) is emerging as the gold standard for intelligent systems in healthcare. This model balances speed and efficiency with explainability and oversight. It also offers a governance and performance evaluation framework that prioritizes human trust. Building AI for HAS Level 3 requires features that go beyond prediction accuracy. Systems must be architected with: Healthcare doesn't need one-size-fits-all automation. It requires collaboration at scale, grounded in transparency and guided by human expertise. These perspectives align perfectly with the Stanford findings: workers don't fear AI—they fear being sidelined by it. The solution isn't to slow down AI development. It's to direct it with clarity, co-design it with the people who rely on it, and evaluate it not just by outputs but also by the experience and empowerment it delivers to human professionals. The true ROI of AI is trust, relief, and time reclaimed. Outcomes like 'claims processed' or 'notes generated' aren't enough. Metrics should track cognitive load reduced, time returned to patient care, and worker trust in AI recommendations. While throughput remains a necessary benchmark, these human-centered outcomes provide the clearest signal of whether AI improves the healthcare experience. Measurement frameworks must be longitudinal, capturing not just initial productivity but long-term operational resilience, clinician satisfaction, and sustainable value. Only then can we ensure that AI fulfills its promise to elevate both performance and purpose in healthcare. Dr. Rohit Chandra, Chief Digital Officer at Cleveland Clinic, gave voice to this idea in June 2025: 'It's made their jobs a ton easier. Patient interactions are a lot better because now patients actually engage with the doctor,' he said, referring to 4,000 physicians now using AI scribes. 'I'm hoping that we can keep building on the success that we've had so far to literally drive the documentation burden to zero.' Build With, Not For This moment is too important for misalignment. The Stanford study offers a blueprint. For healthcare leaders, the message is clear: If you want AI to scale, build with the workforce in mind. Prioritize the Green Light Zones. Invest in agentic systems that enhance, not override. Govern AI like a trusted partner, not a productivity engine. The future of AI in healthcare won't be determined by the size of your model. It will be defined by the quality of your teaming.
Yahoo
an hour ago
- Yahoo
Protest as President Milei's dramatic health care cuts threaten leading Argentine pediatric center
Doctors, residents, and administrative staff from Garrahan Hospital, Argentina's leading pediatric center, protested on Thursday, demanding salary increases from President Javier Milei's government. The unrest at the Garrahan reflects broader dissatisfaction among healthcare professionals under Milei's ultraliberal administration, which has prioritized deep public spending cuts to fight inflation. (AP Video by Victor R. Caivano)
Yahoo
an hour ago
- Yahoo
Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9%
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial growth with the surging prevalence of chronic diseases and advancements in nuclear imaging techniques. The technetium-99m market is expected to reach US$6.29 billion by 2031 from US$ 4.61 billion in 2024; it is anticipated to register a CAGR of 3.9% during the forecast period. Technetium-99m (Tc-99m) is an extensively used radioactive isotope for diagnostic imaging in nuclear medicine. It holds the position of being the most common medical radioisotope worldwide and is used for over 40,000 imaging procedures daily in the US. To explore the valuable insights in the Technetium-99m Market report, you can easily download a sample PDF of the report - Some of the reasons behind Tc-99m's medical popularity are its ideal imaging properties, such as a short half-life of about six hours, suitable gamma energy, as well as providing a low radiation dose, giving it the capability to image organs such as the brain, heart, bones, lungs, kidneys, thyroid, and liver. The development of this market is sustained by increasing demand for Tc-99m-based radiopharmaceuticals in cardiovascular imaging and cancer detection, along with other clinical applications. North America stands as a huge market due to the advanced healthcare infrastructure and high rate of chronic diseases. Asia Pacific is growing fast owing to healthcare infrastructure investments and a focus on advanced diagnostics. The report carries an in-depth analysis of market trends, key players, and future opportunities. The technetium-99m market study focuses on an array of technologies that are expected to fuel the demand in the coming years. For Detailed Technetium-99m Market Insights, Visit: Overview of Report Findings Increasing Chronic Diseases Prevalence: The increase in prevalence of chronic diseases is a much stronger driver for the global Technetium-99m (Tc-99m) market. Tc-99m is the most important radioisotope used in more than 80% of nuclear medicine procedures in the world, mostly used in SPECT scanning for the diagnosis of cancer, cardiovascular diseases, and neurological disorders. According to the International Agency for Research on Cancer, the prevalence of cancer is high worldwide. It is estimated that there were 19.3 million cancer cases globally in 2020, and the number is expected to reach ~30.2 million by 2040. With an increase in the incidence of chronic diseases due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for higher diagnostic imaging techniques rises correspondingly. Such a scenario is evident in Asia Pacific, where chronic diseases such as diabetes and cardiovascular diseases are rising. Health care providers are thus increasingly adopting technetium-based imaging techniques for early diagnosis and for planning of treatment. This rise in demand is favoring the development of the Tc-99m market. Soaring Technological Advancements: Technological discoveries open a whole new set of vistas for the Technetium-99m (Tc-99m) market by making nuclear imaging more efficient, accurate, and accessible. At the forefront of these discoveries are radiopharmaceutical production technologies that include cyclotron-based Tc-99m production that nullifies the need for assessing the aged nuclear reactors and thereby assures more stable Tc-99m supplies. In addition, imaging instrument improvement, mainly within SPECT and hybrid imaging equipment such as SPECT/CT, have increased the resolution and diagnostic ability, thereby increasing Tc-99m's clinical utility. Further, automation in radiopharmacy and simultaneous integration of digital imaging workflows minimize human errors and maximize safety and efficiency. Artificial intelligence and machine learning are further being explored and used for image analysis to provide enhanced and more rapid diagnostic capabilities. Thus, these technological advancements account for the expanding sphere of clinical applications of Tc-99m while reducing operational costs in nuclear medicine, which include its accessibility to emerging markets. Several innovations and various avenues for research, investment, and patient care are being formed in the Tc-99m market. Stay Updated on The Latest Technetium-99m Market Trends: Geographical Insights: In 2024, North America led the technetium-99m market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Market Segmentation By application, the market is categorized into cardiovascular, bone scan, respiratory, tumor imaging, and others. The bone scan segment accounted for the largest share of the market in 2024. Based on end user, the market is segmented into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest share of the market in 2024. The technetium-99m market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: Lantheus Medical Imaging Inc., Curium, Jubilant Pharma Company, NorthStar Medical Radioisotopes LLC, Sun Pharmaceutical Industries Inc., Advancing Nuclear Medicine, NTP Radioisotopes SOC Ltd, Northwest Medical Isotopes LLC, and SHINE Technologies LLC are major companies operating in the market. Trending Topics: Emergence of Hybrid Imaging Techniques, Advancements in Radiopharmaceutical Development, and Sustainability and Cost-Effectiveness Initiatives. Purchase Premium Copy of Global Technetium-99m Market Size and Growth Report (2021-2031) at: Global Headlines on Technetium-99m Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection). BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone. IAEA Launches Research Project to Develop New Technetium-99m Radiopharmaceuticals. Conclusion The demand for technetium-99m is expanding at a rapid pace with increasing requirements for advanced diagnostic imaging, primarily for areas such as oncology, cardiology, and neurology. The largest market for Technetium-99m is North America followed by the easy availability of radiopharmaceuticals and higher average cost of kit for Tc-99m. The technetium-99m market in Asia Pacific is segmented into Japan, China, and India and is also expected to grow at the fastest CAGR due to the increasing investments in improving healthcare infrastructure and rising focus on advanced diagnostics. The development of imaging, such as SPECT and hybrid SPECT/CT systems, is becoming more accurate and reliable in Tc-99m using diagnostics. Furthermore, ongoing development of production technologies, such as non-reactor-based ones address Mo-99 supply chain issues, the progenitor isotope for Tc-99m. Thus, continuous advancements in imaging instruments and manufacturing technologies and government initiatives for bettering nuclear medication facilities are expected to drive the market during the forecast period. The report from The Insight Partners lists several stakeholders—including radiopharmaceutical manufacturers, medical equipment suppliers, healthcare providers, and regulatory bodies—along with valuable insights to navigate this evolving market landscape and unlock new opportunities successfully. For More Latest Life Sciences Research Reports & Industry Analysis - Trending Related Reports: Bone Scan Market Growth, Top Key Players, and Regional Forecast by 2031 Respiratory Disposable Devices Market Size, Trends, Shares, and Forecast – 2031 Respiratory Medical Device Market Size, Trends, Shares, and Forecast – 2031 Respiratory Drug Delivery Devices Market Size, Trends, Shares, and Forecast - 2031 The Tumor Embolization Market Size is expected to register a CAGR of 8.9% from 2025 to 2031 The Heart Tumor Market Size is expected to register a CAGR of 8.0% from 2025 to 2031 The Tumor Ablation Market Size is expected to register a CAGR of 12.5% from 2025 to 2031 The Respiratory Protection Equipment Market Size is expected to register a CAGR of 6.8% from 2025 to 2031 Respiratory Medical Device Professional Market Size Drivers, Opportunities, Trends, and Forecasts by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Press Release - Logo - View original content: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
